Immunomodulatory and clinical effects of receptor-interacting protein kinase 1 (RIPK1) inhibitor eclitasertib (SAR443122) in patients with severe COVID-19: a phase 1b, randomized,...

by Pierre-Francois Clot, Christine Farenc, Benjamin T. Suratt, Tillmann Krahnke, Agnes Tardat, Peter Florian, Robert Pomponio, Naimish Patel, Maria Wiekowski, Yong Lin, Benjamin Terrier, Heribert Staudinger
Published 2024-02-01